Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Asset Utilization Ratio (2021 - 2025)

Cytek Biosciences' Asset Utilization Ratio history spans 5 years, with the latest figure at 0.42 for Q4 2025.

  • For Q4 2025, Asset Utilization Ratio rose 4.12% year-over-year to 0.42; the TTM value through Dec 2025 reached 0.42, up 4.12%, while the annual FY2025 figure was 0.42, 3.96% up from the prior year.
  • Asset Utilization Ratio reached 0.42 in Q4 2025 per CTKB's latest filing, up from 0.4 in the prior quarter.
  • In the past five years, Asset Utilization Ratio ranged from a high of 0.42 in Q4 2025 to a low of 0.0 in Q4 2021.
  • Average Asset Utilization Ratio over 5 years is 0.29, with a median of 0.37 recorded in 2023.
  • The largest YoY upside for Asset Utilization Ratio was 6674.42% in 2022 against a maximum downside of 27.79% in 2022.
  • A 5-year view of Asset Utilization Ratio shows it stood at 0.0 in 2021, then skyrocketed by 6674.42% to 0.32 in 2022, then increased by 18.23% to 0.38 in 2023, then grew by 6.28% to 0.4 in 2024, then rose by 4.12% to 0.42 in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Asset Utilization Ratio are 0.42 (Q4 2025), 0.4 (Q3 2025), and 0.4 (Q2 2025).